Profound Medical Launches AI-Powered Module to Treat Benign Prostatic Hyperplasia
AI Sentiment
Neutral
5/10
as of 12-04-2025 4:00pm EST
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
| Founded: | N/A | Country: | Canada |
| Employees: | N/A | City: | MISSISSAUGA |
| Market Cap: | 189.2M | IPO Year: | N/A |
| Target Price: | $11.00 | AVG Volume (30 days): | 99.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.76 - $8.75 | Next Earning Date: | 11-13-2025 |
| Revenue: | $14,297,000 | Revenue Growth: | 67.94% |
| Revenue Growth (this year): | 64.23% | Revenue Growth (next year): | 113.06% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
PROF Breaking Stock News: Dive into PROF Ticker-Specific Updates for Smart Investing
AI Sentiment
Neutral
5/10
AI Sentiment
Highly Positive
8/10
See how PROF stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "PROF Profound Medical Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.